The story of Viagra, initially marketed by copyright, presents a intricate case study for stakeholders considering the pharmaceutical arena . Despite its groundbreaking success and impact of billions in sales, the patent end has opened the floodgates for generic medications, significantly eroding earnings potential . This change raises questions ab